Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Low frequency of CYP2D6 poor metabolizers among schizophrenia patients

The Pharmacogenomics Journal volume 7, pages 408–410 (2007)Cite this article

Abstract

CYP2D6 has been suggested to be functionally similar to the dopamine transporter. The present study was aimed at analysing the frequency of CYP2D6 alleles and genotype among schizophrenic patients compared to healthy volunteers. CYP2D6 *3, *4, *5, *6, *10 and duplicated alleles were analysed in 128 unselected schizophrenia inpatients (SP) and 142 unrelated white European Spanish healthy volunteers (HV). SP and HV with >2, 2, 1 or 0 CYP2D6 active genes were 4.7, 64.8, 28.1 and 2.3%, and 6.3, 52.1, 33.1 and 8.5%, respectively. The frequency of homozygous for CYP2D6 inactive alleles or poor metabolizers (PMs) was lower (P<0.05) in SP than in HV. Furthermore, the frequency of CYP2D6 inactive alleles was also lower in SP than in HV (16.8 vs 25.7; P<0.05), specifically the CYP2D6*6 allele was not found among patients. The present study shows a lower frequency of PMs in schizophrenic patients than in healthy volunteers supporting the hypothesis of a potential role of CYP2D6 in the vulnerability to schizophrenia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. LLerena A, Cobaleda J, Martinez C, Benitez J . Interethnic differences in drug metabolism: influence of genetic, environmental factors on debrisoquine hydroxylation phenotype. Eur J Drug Metab Pharmacokinet 1996; 21: 129–138.

    Article  CAS  Google Scholar 

  2. Dahl ML . Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41: 453–470.

    Article  CAS  Google Scholar 

  3. LLerena A, Berecz R, de la Rubia A, Fernandez-Salguero P, Dorado P . Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther Drug Monit 2001; 23: 616–620.

    Article  CAS  Google Scholar 

  4. LLerena A, Berecz R, de la Rubia A, Dorado P . QTc interval lengthening is related to CYP2D6 hydroxylation capacity, plasma concentration of thioridazine in patients. J Psychopharmacol 2002; 16: 361–364.

    Article  CAS  Google Scholar 

  5. LLerena A, Berecz R, Dorado P, de la Rubia A . QTc interval, CYP2D6, CYP2C9 genotypes, risperidone plasma concentrations. J Psychopharmacol 2004; 18: 189–193.

    Article  CAS  Google Scholar 

  6. LLerena A, de la Rubia A, Berecz R, Dorado P . Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6, CYP2C9 genotypes in psychiatric patients. Pharmacopsychiatry 2004; 37: 69–73.

    Article  CAS  Google Scholar 

  7. Berecz R, de la Rubia A, Dorado P, Fernandez-Salguero P, Dahl ML, LLerena A . Thioridazine steady-state plasma concentrations are influenced by tobacco smoking, CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 2003; 59: 45–50.

    Article  CAS  Google Scholar 

  8. Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M . Cellular localization, regional distribution of CYP2D6 mRNA, protein expression in human brain. Pharmacogenetics 2001; 11: 237–245.

    Article  CAS  Google Scholar 

  9. Miksys S, Rao Y, Hoffmann E, Mash DC, Tyndale RF . Regional, cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 2002; 82: 1376–1387.

    Article  CAS  Google Scholar 

  10. LLerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L . Relationship between personality, debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psych Scand 1993; 87: 23–28.

    Article  CAS  Google Scholar 

  11. Bradford LD . CYP2D6 allele frequency in European Caucasians, Asians, Africans, their descendants. Pharmacogenomics 2002; 3: 229–243.

    Article  CAS  Google Scholar 

  12. Johansson I, Oscarson M, Yue Q-Y, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M . Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452–459.

    CAS  PubMed  Google Scholar 

  13. Dawson E, Powell JF, Nothen MM, Crocq MA, Lanczik M, Korner J et al. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia. Psychiatr Genet 1994; 4: 215–218.

    Article  CAS  Google Scholar 

  14. Daniels J, Williams J, Asherson P, McGuffin P, Owen M . No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT). Am J Med Genet 1995; 60: 85–87.

    Article  CAS  Google Scholar 

  15. Pirmohamed M, Wild MJ, Kitteringham NR, O’Brien K, Buchan IE, Back DJ et al. Lack association between schizophrenia and the CYP2D6 gene polymorphisms. Am J Med Genet 1996; 67: 236–237.

    Article  CAS  Google Scholar 

  16. Jonsson EG, Dahl ML, Roh HK, Jerling M, Sedvall GC . Lack of association between debrisoquine 4-hydroxylase (CYP2D6) gene polymorphisms and schizophrenia. Psychiatr Genet 1998; 8: 25–28.

    Article  CAS  Google Scholar 

  17. Chen CH, Hung CC, Wei FC, Koong FJ . Debrisoquine 4-hydroxylase (CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan. Psychiatr Genet 2001; 11: 153–155.

    Article  CAS  Google Scholar 

  18. Brockmoller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Muller-Oerlinghausen B et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438–452.

    Article  Google Scholar 

  19. Dahl AA, Løwert A, Asserson S, Bjarking L, Berglund J, Kristensen F et al. Hydroxylation polymorphism of debrisoquine hydroxylase (CYP2D6) in patients with schizophrenia in Norway and Denmark. Hum Psychopharmacol 1998; 13: 509–511.

    Article  Google Scholar 

  20. Dorado P, Caceres MC, Pozo-Guisado E, Wong ML, Licinio J, Llerena A . Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 2005; 39: 571–574.

    Article  Google Scholar 

  21. Hiroi T, Imaoka S, Funae Y . Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 1998; 249: 838–843.

    Article  CAS  Google Scholar 

  22. Yu AM, Idle JR, Byrd LG, Krausz KW, Kupfer A, Gonzalez FJ . Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003; 13: 173–181.

    Article  CAS  Google Scholar 

  23. Niwa T, Hiroi T, Tsuzuki D, Yamamoto S, Narimatsu S . Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res 2004; 129: 117–123.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Supported by Plan Nacional de Investigaciòn Cientifica, Desarrollo e Innovaciòn Tecnológica (I+D+I) and European Union, Fondo Social Europeo (FEDER), Ministerio de Educaciòn y Ciencia (SAF2006-13589), and Consejería de Sanidad y Consumo, Junta de Extremadura (SCSS0575), and coordinated in the CYTED network Red Iberoamericana de Farmacogenética y Farmacogenómica (206RT0290). PD and MCCL are supported by grants from Junta de Extremadura, Consejería de Infraestructura y Desarrollo Tecnológico and Unión Europea, Fondo Social Europeo (REI05A003) and (FIC04A096), respectively.

Author information

Authors and Affiliations

  1. Department of Pharmacology and Psychiatry, School of Medicine, University of Extremadura, Badajoz, Spain

    A LLerena, P Dorado, E M Peñas-LLedó & M C Cáceres

  2. Hospital Universitario Infanta Cristina, CICAB-FundeSalud, Servicio Extremeño de Salud, Badajoz, Spain

    A LLerena

  3. Mérida Psychiatric Hospital, Mérida, Spain

    A De la Rubia

Authors
  1. A LLerena
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Dorado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E M Peñas-LLedó
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M C Cáceres
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A De la Rubia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A LLerena.

Additional information

Duality of interest

None of the authors has a conflict of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Cite this article

LLerena, A., Dorado, P., Peñas-LLedó, E. et al. Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J 7, 408–410 (2007). https://doi.org/10.1038/sj.tpj.6500439

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500439

Keywords

This article is cited by

Search

Advanced search

Quick links